<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47047">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02087527</url>
  </required_header>
  <id_info>
    <org_study_id>HGNPE-128-2013</org_study_id>
    <nct_id>NCT02087527</nct_id>
  </id_info>
  <brief_title>Use of Corticosteroids in Children With Cellulitis</brief_title>
  <official_title>Use of Corticosteroids in Children Hospitalized With Cellulitis: Randomized, Double Blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Niños Pedro de Elizalde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Niños Pedro de Elizalde</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of addition of corticosteroid therapy to
      antibiotic treatment during the first 48 hours of admission to the hospital in patients with
      cellulitis and its impact in the duration of the stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cellulitis is a common skin and soft tissue infection in the pediatric population.

      Although most of the time treatment could be administered on an ambulatory setting ,
      sometimes it may require hospitalization and parenteral antibiotic administration. Using
      corticosteroids during antibiotic treatment may reduce inflammation and length of stay.

      Objective: to evaluate the efficacy of using corticosteroids as adjuvant treatment during
      the first 48 hours of treatment after hospitalization in patients with cellulitis.

      Patients and methods: this is a double blind, randomized, controlled trial that will take
      place at pediatric hospital, during one year. It will include children aged 1 month to 18
      years, admitted due to cellulitis. Once included in the clinical trial, the patients will be
      randomized to receive dexamethasone 0,6 mg/kg/day or placebo (saline solution) during the
      first 48 hours. Considering an average stay of 4 ± 2 days, we calculated a sample size of
      124 children (62 children per group) to detect a 25% difference (1 day reduction) in the
      length of stay, with a power of 80% and a confidence of 95%.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Length of stay</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 5 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fever duration</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 5 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erythema size</measure>
    <time_frame>Measured at admission and after 48 hours (at the end of corticosteroids treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need to change antibiotic treatment</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 5 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abscessation or spontaneous drainage</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 5 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Cellulitis</condition>
  <arm_group>
    <arm_group_label>CORTICOSTEROID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to standard care for cellulitis, subject will receive intravenous Dexamethasone (8mg/2ml) 0.15 mg/kg/dose every 6 hours for the first 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NORMAL SALINE</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In addition to standard care for cellulitis, subject will receive normal saline solution administered intravenously using the same volume as the active drug group every 6 hours for the first 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>IV Dexamethasone 0.15 mg/kg every 6 hours for 48 hours</description>
    <arm_group_label>CORTICOSTEROID</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>IV normal saline every 6 hours for 48 hours</description>
    <arm_group_label>NORMAL SALINE</arm_group_label>
    <other_name>ClNa 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children Aged 1 month to 18 years

          -  Hospitalized due to cellulitis

          -  Patients who have given their written informed consent to participate

        Exclusion Criteria:

          -  Skin chronic diseases

          -  Immunodeficiency (primary or acquired)

          -  Chronic use of systemic corticosteroids

          -  Sepsis

          -  Varicella

          -  History of adrenal insufficiency

          -  Pregnancy or breast feeding

          -  Uncontrolled diabetes mellitus

          -  Known hypersensitivity to systemic or topical corticosteroids

          -  Patient undergoing immunosuppressive therapy for another disease

          -  Participation in another drug biomedical research

          -  Any other contraindication for treatment with corticosteroids
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emiliano G Gigliotti, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General de Niños Pedro de Elizalde</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cinthia Keshishian, MD</last_name>
    <phone>+541143070140</phone>
    <email>a_mi_sola@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Romina Carrano, MD</last_name>
    <email>romicarrano@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de NIños Pedro de Elizalde</name>
      <address>
        <city>Buenos Aires</city>
        <state>CF</state>
        <zip>C1270AAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando Ferrero, MD, PhD</last_name>
      <phone>+ 54 11 43070140</phone>
      <email>fferrero@intramed.net</email>
    </contact>
    <contact_backup>
      <last_name>Maria F Ossorio, MD</last_name>
      <phone>+54 11 43632100</phone>
      <phone_ext>1014</phone_ext>
      <email>mossorio@intramed.net</email>
    </contact_backup>
    <investigator>
      <last_name>Cinthia Keshishian, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romina Carrano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Rojas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julieta Barabas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romina Gola, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Bergkvist PI, Sjöbeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis. 1997;29(4):377-82.</citation>
    <PMID>9360253</PMID>
  </reference>
  <reference>
    <citation>McGowan JE Jr, Chesney PJ, Crossley KB, LaForce FM. Guidelines for the use of systemic glucocorticosteroids in the management of selected infections. Working Group on Steroid Use, Antimicrobial Agents Committee, Infectious Diseases Society of America. J Infect Dis. 1992 Jan;165(1):1-13.</citation>
    <PMID>1727879</PMID>
  </reference>
  <reference>
    <citation>Thompson J. Role of glucocorticosteroids in the treatment of infectious diseases. Eur J Clin Microbiol Infect Dis. 1993;12 Suppl 1:S68-72. Review.</citation>
    <PMID>8477768</PMID>
  </reference>
  <reference>
    <citation>Fritz KA, Weston WL. Systemic glucocorticosteroid therapy of skin disease in children. Pediatr Dermatol. 1984 Jan;1(3):236-45. Review.</citation>
    <PMID>6387668</PMID>
  </reference>
  <reference>
    <citation>Jaussaud R, Kaeppler E, Strady C, Beguinot I, Waldner A, Rémy G. [Should NSAID/corticoids be considered when treating erysipelas?]. Ann Dermatol Venereol. 2001 Mar;128(3 Pt 2):348-51. Review. French.</citation>
    <PMID>11319363</PMID>
  </reference>
  <reference>
    <citation>Kilburn SA, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD004299. doi: 10.1002/14651858.CD004299.pub2. Review.</citation>
    <PMID>20556757</PMID>
  </reference>
  <reference>
    <citation>Pushker N, Tejwani LK, Bajaj MS, Khurana S, Velpandian T, Chandra M. Role of oral corticosteroids in orbital cellulitis. Am J Ophthalmol. 2013 Jul;156(1):178-183.e1. doi: 10.1016/j.ajo.2013.01.031. Epub 2013 Apr 24.</citation>
    <PMID>23622565</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>February 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cellulitis</keyword>
  <keyword>Soft Tissue Infections</keyword>
  <keyword>Skin Diseases, Infectious</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Dexamethasone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cellulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
